MinION: A novel tool for predicting drug hypersensitivity?

Research output: Contribution to journalShort survey

2 Citations (Scopus)

Abstract

The launch of the MinION Access Program has caused much activity within the scientific community. MinION represents a keenly anticipated, novel addition to the current melange of commercial sequencers. Driven by the nanopore sequencing mechanism that requires minimal sample manipulation, the device is capable of generating long sequence reads in sizes (up to or exceeding 50 kb) that surpass those of all other platforms. One notable advantage of this feature is that long-range haplotypes can be more accurately resolved; such advantage is particularly pertinent to the genotyping of complex loci such as genes encoding the human leukocyte antigens, which are pivotal determinants of drug hypersensitivity. With this timely, albeit brief, review, we set out to examine the applications on which MinION has been tested thus far, the bioinformatics workflow tailored to the unique characteristics of its extended sequence reads, the device's potential utility in the detection of genetic markers for drug hypersensitivity, and how it may eventually evolve to become fit for diagnostic purposes in the clinical setting.

Original languageEnglish
Article number156
JournalFrontiers in Pharmacology
Volume7
Issue numberJUN
DOIs
Publication statusPublished - 14 Jun 2016

Fingerprint

Drug Hypersensitivity
Nanopores
Equipment and Supplies
Workflow
HLA Antigens
Computational Biology
Genetic Markers
Haplotypes
Genes

Keywords

  • Bioinformatics analysis
  • Drug hypersensitivity
  • MinION
  • Nanopore sequencing
  • Sequence-based HLA typing

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

MinION : A novel tool for predicting drug hypersensitivity? / Chua, Eng Wee; Ng, Pei Yuen.

In: Frontiers in Pharmacology, Vol. 7, No. JUN, 156, 14.06.2016.

Research output: Contribution to journalShort survey

@article{44db5be141e24788bfe4238bb71b2f36,
title = "MinION: A novel tool for predicting drug hypersensitivity?",
abstract = "The launch of the MinION Access Program has caused much activity within the scientific community. MinION represents a keenly anticipated, novel addition to the current melange of commercial sequencers. Driven by the nanopore sequencing mechanism that requires minimal sample manipulation, the device is capable of generating long sequence reads in sizes (up to or exceeding 50 kb) that surpass those of all other platforms. One notable advantage of this feature is that long-range haplotypes can be more accurately resolved; such advantage is particularly pertinent to the genotyping of complex loci such as genes encoding the human leukocyte antigens, which are pivotal determinants of drug hypersensitivity. With this timely, albeit brief, review, we set out to examine the applications on which MinION has been tested thus far, the bioinformatics workflow tailored to the unique characteristics of its extended sequence reads, the device's potential utility in the detection of genetic markers for drug hypersensitivity, and how it may eventually evolve to become fit for diagnostic purposes in the clinical setting.",
keywords = "Bioinformatics analysis, Drug hypersensitivity, MinION, Nanopore sequencing, Sequence-based HLA typing",
author = "Chua, {Eng Wee} and Ng, {Pei Yuen}",
year = "2016",
month = "6",
day = "14",
doi = "10.3389/fphar.2016.00156",
language = "English",
volume = "7",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - MinION

T2 - A novel tool for predicting drug hypersensitivity?

AU - Chua, Eng Wee

AU - Ng, Pei Yuen

PY - 2016/6/14

Y1 - 2016/6/14

N2 - The launch of the MinION Access Program has caused much activity within the scientific community. MinION represents a keenly anticipated, novel addition to the current melange of commercial sequencers. Driven by the nanopore sequencing mechanism that requires minimal sample manipulation, the device is capable of generating long sequence reads in sizes (up to or exceeding 50 kb) that surpass those of all other platforms. One notable advantage of this feature is that long-range haplotypes can be more accurately resolved; such advantage is particularly pertinent to the genotyping of complex loci such as genes encoding the human leukocyte antigens, which are pivotal determinants of drug hypersensitivity. With this timely, albeit brief, review, we set out to examine the applications on which MinION has been tested thus far, the bioinformatics workflow tailored to the unique characteristics of its extended sequence reads, the device's potential utility in the detection of genetic markers for drug hypersensitivity, and how it may eventually evolve to become fit for diagnostic purposes in the clinical setting.

AB - The launch of the MinION Access Program has caused much activity within the scientific community. MinION represents a keenly anticipated, novel addition to the current melange of commercial sequencers. Driven by the nanopore sequencing mechanism that requires minimal sample manipulation, the device is capable of generating long sequence reads in sizes (up to or exceeding 50 kb) that surpass those of all other platforms. One notable advantage of this feature is that long-range haplotypes can be more accurately resolved; such advantage is particularly pertinent to the genotyping of complex loci such as genes encoding the human leukocyte antigens, which are pivotal determinants of drug hypersensitivity. With this timely, albeit brief, review, we set out to examine the applications on which MinION has been tested thus far, the bioinformatics workflow tailored to the unique characteristics of its extended sequence reads, the device's potential utility in the detection of genetic markers for drug hypersensitivity, and how it may eventually evolve to become fit for diagnostic purposes in the clinical setting.

KW - Bioinformatics analysis

KW - Drug hypersensitivity

KW - MinION

KW - Nanopore sequencing

KW - Sequence-based HLA typing

UR - http://www.scopus.com/inward/record.url?scp=84977621720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977621720&partnerID=8YFLogxK

U2 - 10.3389/fphar.2016.00156

DO - 10.3389/fphar.2016.00156

M3 - Short survey

AN - SCOPUS:84977621720

VL - 7

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUN

M1 - 156

ER -